NeoGenomics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NeoGenomics and other ETFs, options, and stocks.

About NEO

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments.

CEO

Christopher Michael Smith

CEOChristopher Michael Smith

Employees

2,100

Employees2,100

Headquarters

Fort Myers, Florida

HeadquartersFort Myers, Florida

Founded

1998

Founded1998

Employees

2,100

Employees2,100

NEO Key Statistics

Market cap

1.74B

Market cap1.74B

Price-Earnings ratio

-19.84

Price-Earnings ratio-19.84

Dividend yield

—

Dividend yield—

Average volume

1.08M

Average volume1.08M

High today

$14.36

High today$14.36

Low today

$13.51

Low today$13.51

Open price

$14.00

Open price$14.00

Volume

236.87K

Volume236.87K

52 Week high

$21.22

52 Week high$21.22

52 Week low

$11.03

52 Week low$11.03

NEO News

Benzinga 21h

Where NeoGenomics Stands With Analysts - NeoGenomics - Benzinga

Loading... Loading... Ratings for NeoGenomics NEO were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives....

Yahoo Finance 1d

NeoGenomics Q1 2024 Earnings: Revenue Surpasses Estimates, Net Loss Narrows - Yahoo Finance

Revenue: Reached $156 million in Q1 2024, up 14% year-over-year, surpassing estimates of $149.89 million. Net Loss: Decreased to $27 million in Q1 2024, down 1...

Yahoo Finance 1d

NeoGenomics Reports First Quarter 2024 Results - Yahoo Finance

First Quarter Revenue Increased 14% to $156 Million FORT MYERS, Fla., April 30, 2024--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO) (the "Company"), a leadi...

Analyst ratings

77%

of 13 ratings

Buy

76.9%

Hold

23.1%

Sell